(NASDAQ: LVTX) Lava Therapeutics Nv's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.75%.
Lava Therapeutics Nv's earnings in 2025 is -$31,506,741.On average, 3 Wall Street analysts forecast LVTX's earnings for 2025 to be -$33,757,585, with the lowest LVTX earnings forecast at -$43,929,843, and the highest LVTX earnings forecast at -$22,096,448. On average, 3 Wall Street analysts forecast LVTX's earnings for 2026 to be -$14,028,614, with the lowest LVTX earnings forecast at -$15,783,177, and the highest LVTX earnings forecast at -$12,363,489.
In 2027, LVTX is forecast to generate -$10,608,925 in earnings, with the lowest earnings forecast at -$12,626,542 and the highest earnings forecast at -$8,680,747.